Skip to main content

Table 1 Baseline Characteristics of the participants

From: Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy — a cohort study

Variables Cisplatin Group n = 200 n (%) Non-Cisplatin Group n = 200 n (%)
1 Age (yrs)a 56 (11.9) 55 (9)
2 Males 108 (54%) 104 (52%)
3 Time to VTE (days)a 58 (17) 56 (13)
4 Stage
  Early 10 (5%) 12 (6%)
  Locally advanced 86 (43%) 92 (46%)
  Metastatic 104 (52%) 96 (48%)
5 Presence of CVC 58 (29%) 55 (27%)
6 Surgery in 2 months 44 (22%) 56 (28%)
7 ECOG poor 16 (8%) 12 (6%)
8 Khorana Risk
  low 39(19.5%) 55 (27.5%)
  intermediate 129 (64.5%) 125 (62.5%)
  high 32 (16%) 20 (10%)
9 Use of GCSF
  never 88 (44%) 86 (43%)
  <50% of cycles 71 (35.5%) 81 (40.5%)
  >50% of cycles 6 (3%) 24 (12%)
  All cycles 35 (17.5%) (9 9.5%)
  1. aMean(SD)